Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Current Deferred Revenue (2022 - 2024)

Praxis Precision Medicines has reported Current Deferred Revenue over the past 3 years, most recently at $1.2 million for Q3 2024.

  • Quarterly results put Current Deferred Revenue at $1.2 million for Q3 2024, down 24.61% from a year ago — trailing twelve months through Sep 2024 was $1.2 million (down 24.61% YoY), and the annual figure for FY2023 was $1.4 million, down 72.16%.
  • Current Deferred Revenue for Q3 2024 was $1.2 million at Praxis Precision Medicines, down from $1.2 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for PRAX hit a ceiling of $5.0 million in Q4 2022 and a floor of $1.2 million in Q3 2024.
  • Median Current Deferred Revenue over the past 3 years was $1.5 million (2023), compared with a mean of $2.0 million.
  • Biggest five-year swings in Current Deferred Revenue: plummeted 72.16% in 2023 and later decreased 24.61% in 2024.
  • Praxis Precision Medicines' Current Deferred Revenue stood at $5.0 million in 2022, then plummeted by 72.16% to $1.4 million in 2023, then dropped by 15.95% to $1.2 million in 2024.
  • The last three reported values for Current Deferred Revenue were $1.2 million (Q3 2024), $1.2 million (Q2 2024), and $1.3 million (Q1 2024) per Business Quant data.